Momenta Pharmaceuticals, Inc. - News/Events - Press Releases

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004

11/29/2016

Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA® (adalimumab) Biosimilar

11/17/2016

Momenta Pharmaceuticals Announces Publication on the Design of M230, a Novel Autoimmune Disease Drug Candidate, in Science Translational Medicine

11/02/2016

Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)

11/02/2016

Momenta Pharmaceuticals Appoints Scott M. Storer as Senior Vice President and Chief Financial Officer

11/02/2016

Momenta Pharmaceuticals Reports Third Quarter 2016 Financial Results

10/31/2016

Momenta Pharmaceuticals to Webcast at Two Upcoming Investor Conferences

10/20/2016

Momenta Pharmaceuticals Announces Date for Third Quarter 2016 Financial Results Conference Call and Webcast

09/27/2016

Momenta Pharmaceuticals to Regain Global Development and Commercialization Rights to M923, a Proposed Biosimilar of HUMIRA® (adalimumab), Through Termination of Collaboration Agreement with Baxalta, Now Part of Shire

09/23/2016

Momenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors

08/31/2016

Momenta Pharmaceuticals to Webcast Presentation at the 2016 Wells Fargo Healthcare Conference

08/04/2016

Momenta Pharmaceuticals Reports Second Quarter 2016 Financial Results

08/04/2016

Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis

07/21/2016

Momenta Pharmaceuticals Announces Date for Second Quarter 2016 Financial Results Conference Call and Webcast

06/23/2016

Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors

06/09/2016

Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody

06/08/2016

Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA® (adalimumab) Biosimilar, at EULAR 2016

06/04/2016

Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO

05/25/2016

Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 37th Annual Global Healthcare Conference

05/19/2016

Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting

05/03/2016

Momenta Pharmaceuticals Reports First Quarter 2016 Financial Results

04/26/2016

Momenta Pharmaceuticals Announces Time Change for First Quarter 2016 Financial Results Conference Call and Webcast

04/25/2016

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

04/19/2016

Momenta Pharmaceuticals Announces Date of First Quarter 2016 Financial Results Conference Call and Webcast

03/09/2016

Momenta Pharmaceuticals Appoints Jose-Carlos Gutierrez-Ramos, Ph.D. to Board of Directors

02/24/2016

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

02/18/2016

Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results

02/10/2016

Momenta Pharmaceuticals Announces Early HSR Clearance for Biosimilars Collaboration With Mylan

02/05/2016

Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2015 Financial Results Conference Call and Webcast

02/01/2016

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

01/08/2016

Momenta Pharmaceuticals Announces Worldwide Collaboration With Mylan to Jointly Develop and Commercialize Six Biosimilar Products

01/05/2016

Momenta Pharmaceuticals to Webcast Presentation at the 34th Annual J. P. Morgan Healthcare Conference